Exocrine Pancreatic Cancer Clinical Trial
Official title:
A Phase 0 Study of High Dose Omeprazole in Patients With Pancreatic Cancer Planning to Undergo Surgical Therapy for Evaluating Changes of Biomarkers
The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.
During this study patients will receive treatment of omeprazole at the dose depending on group enrollment - Group A will receive omeprazole 80 mg, twice a day for 14 days unless unacceptable toxicity - Group B, will receive omeprazole 20 mg, once a day for 14 days Patients will receive treatment for 2~3 weeks during the study, and 2 months of follow up. Total accrual is anticipated to take 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04011982 -
PATAKESS Protocol : Clinical and Biological Analysis of Exocrine Pancreatic Tumors
|
||
| Completed |
NCT01020006 -
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
|
Phase 2 | |
| Recruiting |
NCT03485209 -
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
|
Phase 2 |